MétaCan
Menu
Back to cohort

Abstract P1-14-05: Is there a correlation between androgen receptor (AR) expression in metastatic breast cancer (MBC) ER+/Her2- and response to anti-estrogen treatment?

2013· article· en· W2018755246 on OpenAlexaff
MC Riesco Martínez, Wedad Hanna, Zeina Ghorab, Ellen Warner

Bibliographic record

VenueCancer Research · 2013
Typearticle
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsSunnybrook Health Science Centre
Fundersnot available
KeywordsMedicineEstrogen receptorMetastatic breast cancerBreast cancerAntiestrogenInternal medicineOncologyCancerEstrogenImmunohistochemistryAntiandrogenEndocrine systemAndrogen receptorGynecologyGastroenterologyProstate cancerHormone

Abstract

fetched live from OpenAlex

Abstract Background: AR expression varies significantly according to molecular breast cancer phenotype, being more common in Luminal A and B tumors where it is found in 68 to 95% of primary tumours(1) AR expression has been related to good prognostic features2 and may be lost with the appearance of metastatic disease (2), however its relationship to anti-estrogen treatment response has not been previously described. Since AR may also be a target for antiandrogen therapy for patients who have progressed on antiestrogen therapy, knowledge of which cancers are most likely to test positive for AR would be helpful. Objectives: To correlate the rate and intensity of AR expression in ER+ / PR+ve HER2 –ve MBC tumors with response rate and duration to antiestrogen treatment. Methods: Thirty-two patients with ER+/PR+ve, Her2-ve MBC seen in our centre since 2008 who had received endocrine treatment and had an available biopsy from any metastatic site were randomly selected. Patients who had progressed on endocrine adjuvant treatment were excluded. Immunohistochemical examination to assess AR expression was performed on the specimens of the metastatic and primary tumor if available. Pts were classified into 3 categories according to their response to anti-estrogen treatment: A)good response: 24 months(m), B) intermediate: 6-24m and C) poor response:6m. Results: 46 samples from 32 patients (median age 55 years, range 31-90) were analyzed. Response to anti-estrogen therapy was 59% (19/32), 28% (9/32) and 12% (4/32)for categories A, B, and C respectively. Five pts (16%) had samples from both primary and at least one metastasis. AR was +ve in 100% of the 5 primary tumor samples and 90% (37/41) of the metastases. The 4 AR –ve samples were from different pts, 3 in response category A and one in C. AR expression in the primary and metastatic site was concordant in 40% (2/5) samples. Among the 5 patients with samples from more than one metastatic site 100% concordance was found when different metastatic sites from the same pt were analyzed. Intensity of AR expression was found to be strongly +ve in 85% of the samples (34/40), moderately +ve in 12,5% (5/40)and weakly +ve in 2.5% (1/40). Primary and metastatic samples expressed of pts correlated in 100% of cases. No statistically significant differences were found between the intensity of the staining and the response to hormone therapy (p = 0.387). Conclusion: The great majority (90%) of tumours of our cohort of patients with mBC ER+ and/or PR+ were also AR+. There was no correlation between response to anti-estrogen therapy and either AR expression or intensity. Response to anti-estrogen treatment cannot be used as a guide to determine which patients might be candidates for AR testing and for a trial of anti-androgen therapy. REFERENCES 1. Moinfar F,et al.Cancer 2003. 2. Cimino-Mathews A,et al. Human Pathol 2012. 3. Ogawa Y,et al. Int J Clin Oncol 2008. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-14-05.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.517
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.068
GPT teacher head0.406
Teacher spread0.338 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicAdvanced Breast Cancer TherapiesFrench-language works237,207